drugset
drugset / Trial / NCT02334449

First-in-human Study to Assess the Safety and Pharmacokinetics of LML134 in Healthy Volunteers

NCT02334449 ↗

Phase 1 Completed 133 enrolled Novartis Pharmaceuticals
Parallel-groupQuadruple-blindTreatment

Summary

Phase I study to assess the safety, tolerability and pharmacokinetics of ascending single and multiple doses of the investigational medicinal product in healthy volunteers

Timeline

Start
2015-02
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject LML134 Small molecule — —

Indications

No indication recorded.